balaglitazone
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00515632)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Peroxisome proliferator-activated receptor gammaPARTIAL AGONIST
PPARG partial agonist
Discontinueddue to safety concerns
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O- Mol. weight
- 395.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103991 ↗
Also known as
- balaglitazone
- balaglitazone
- balaglitazone
- balaglitazone
- drf-2593
- drf-2593
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00515632 | Phase 3 | Jul 1, 2007 | Nordic Bioscience |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nordic Bioscience | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1